Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

B. Riley Securities Downgrades IN8bio to Neutral, Lowers Price Target to $3

B. Riley Securities analyst Kalpit Patel downgrades IN8bio (NASDAQ:INAB) from Buy to Neutral and lowers the price target from $9 to $3.

byBenzinga Newsdesk

November 11, 2022

1 minute read

B. Riley Securities analyst Kalpit Patel downgrades IN8bio (NASDAQ:INAB) from Buy to Neutral and lowers the price target from $9 to $3.

The Estee Lauder Cos Q4 EPS $0.42 Beats $0.34 Estimate, Sales $3.94B Beat $3.43B Estimate

By Benzinga Newsdesk

Today, 11:09 PM

The Estee Lauder Cos (NYSE:EL) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.34 by 23.53 percent. This is a 46.15 percent decrease over earnings of $0.78 per share from

B of A Securities Maintains Underperform on Wolfspeed, Lowers Price Target to $75

By Benzinga Newsdesk

Today, 11:09 PM

B of A Securities analyst Vivek Arya maintains Wolfspeed (NYSE:WOLF) with a Underperform and lowers the price target from $95 to $75.

WOLF

News

Eisai And Biogen Announced Today That Eisai Has Submitted A Marketing Authorization Application For Lecanemab For The Treatment Of Early Alzheimer’s Disease In Japan

By Charles Gross

Today, 11:09 PM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.

BIIB